Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 30, Number 6—June 2024
Research Letter

Evaluating Humoral Immunity Elicited by XBB.1.5 Monovalent COVID-19 Vaccine

Xammy Huu Nguyenla, Timothy A. Bates, Mila Trank-Greene, Mastura Wahedi, Fikadu G. TafesseComments to Author , and Marcel CurlinComments to Author 
Author affiliation: Oregon Health and Science University, Portland, Oregon, USA

Main Article

Figure

SARS-CoV-2 antibody titers in an evaluation of humoral immunity elicited by XBB.1.5 monovalent COVID-19 vaccine. A) Duplicate wells infected with live SARS-CoV-2 virus at serially diluted titers. OD was measured at 492 nm using a CLARIOstar plate reader (BMG LABTECH, https://www.bmglabtech.com). Wells were stained and counted to create representative FRNT50 curve at right. B) Preboost and postboost serum antibody isotype titers against spike RBD. C) Neutralizing titers against live ancestral (WT) SARS-CoV-2 and variants. GMT for each bar was calculated in Prism (GraphPad Software Inc., https://www.graphpad.com). All individual data points are displayed as filled circles. Boost ratios were calculated by dividing the post-XBB.1.5 vaccination GMT (postboost) by pre-vaccination GMT (preboost). Reported p values were calculated using restricted effect maximum-likelihood model (B) or 1-way repeated measures analysis of variance (C) with Šídák's multiple comparisons tests. EC50, 50% ELISA effective concentration; FRNT50, 50% focus reduction neutralization; GMT, geometric mean titer; LOD, lower limit of detection; OD, optical density; WT, wild-type.

Figure. SARS-CoV-2 antibody titers in an evaluation of humoral immunity elicited by XBB.1.5 monovalent COVID-19 vaccine. A) Duplicate wells infected with live SARS-CoV-2 virus at serially diluted titers. OD was measured at 492 nm using a CLARIOstar plate reader (BMG LABTECH, https://www.bmglabtech.com). Wells were stained and counted to create representative FRNT50 curve at right. B) Preboost and postboost serum antibody isotype titers against spike RBD. C) Neutralizing titers against live ancestral (WT) SARS-CoV-2 and variants. GMT for each bar was calculated in Prism (GraphPad Software Inc., https://www.graphpad.com). All individual data points are displayed as filled circles. Boost ratios were calculated by dividing the post-XBB.1.5 vaccination GMT (postboost) by pre-vaccination GMT (preboost). Reported p values were calculated using restricted effect maximum-likelihood model (B) or 1-way repeated measures analysis of variance (C) with Šídák's multiple comparisons tests. EC50, 50% ELISA effective concentration; FRNT50, 50% focus reduction neutralization; GMT, geometric mean titer; LOD, lower limit of detection; OD, optical density; WT, wild-type.

Main Article

Page created: April 05, 2024
Page updated: April 26, 2024
Page reviewed: April 26, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external